COVID-19 mRNA Vaccine Safety Among Children Aged 6 Months-5 Years - United States, June 18, 2022-August 21, 2022.
作者信息
Hause Anne M, Marquez Paige, Zhang Bicheng, Myers Tanya R, Gee Julianne, Su John R, Parker Casey, Thompson Deborah, Panchanathan Sarada S, Shimabukuro Tom T, Shay David K
出版信息
MMWR Morb Mortal Wkly Rep. 2022 Sep 2;71(35):1115-1120. doi: 10.15585/mmwr.mm7135a3.
Abstract
摘要
相似文献
1
COVID-19 mRNA Vaccine Safety Among Children Aged 6 Months-5 Years - United States, June 18, 2022-August 21, 2022.2022年6月18日至2022年8月21日美国6个月至5岁儿童中新冠病毒mRNA疫苗的安全性
MMWR Morb Mortal Wkly Rep. 2022 Sep 2;71(35):1115-1120. doi: 10.15585/mmwr.mm7135a3.
2
COVID-19 mRNA vaccine safety during the first 6 months of roll-out in the USA.美国新冠病毒mRNA疫苗在推广的前6个月期间的安全性。
Lancet Infect Dis. 2022 Jun;22(6):747-748. doi: 10.1016/S1473-3099(22)00123-2. Epub 2022 Mar 7.
3
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021.mRNA COVID-19 疫苗接种后出现心肌炎报告：免疫实践咨询委员会更新-美国，2021 年 6 月。
MMWR Morb Mortal Wkly Rep. 2021 Jul 9;70(27):977-982. doi: 10.15585/mmwr.mm7027e2.
4
Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022.2、3 和 4 剂 COVID-19 mRNA 疫苗在 SARS-CoV-2 奥密克戎 BA.1 和 BA.2/BA.2.12.1 亚谱系占主导地位期间对免疫功能正常成年人的有效性 - VISION 网络，10 个州，2021 年 12 月至 2022 年 6 月。
MMWR Morb Mortal Wkly Rep. 2022 Jul 22;71(29):931-939. doi: 10.15585/mmwr.mm7129e1.
5
Safety Monitoring of an Additional Dose of COVID-19 Vaccine - United States, August 12-September 19, 2021.COVID-19 疫苗追加剂量的安全性监测 - 美国，2021 年 8 月 12 日至 9 月 19 日。
MMWR Morb Mortal Wkly Rep. 2021 Oct 1;70(39):1379-1384. doi: 10.15585/mmwr.mm7039e4.
6
Safety Monitoring of COVID-19 mRNA Vaccine First Booster Doses Among Persons Aged ≥12 Years with Presumed Immunocompromise Status - United States, January 12, 2022-March 28, 2022.2022 年 1 月 12 日至 2022 年 3 月 28 日期间，针对疑似免疫功能低下的≥12 岁人群接种 COVID-19 mRNA 疫苗加强针的安全性监测-美国。
MMWR Morb Mortal Wkly Rep. 2022 Jul 15;71(28):899-903. doi: 10.15585/mmwr.mm7128a3.
7
Myocarditis Cases After mRNA-Based COVID-19 Vaccination in the US.美国基于mRNA的新冠疫苗接种后的心肌炎病例
JAMA. 2022 May 24;327(20):2019-2020. doi: 10.1001/jama.2022.5131.
8
Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink.疫苗安全数据链接中 COVID-19 疫苗接种后吉兰-巴雷综合征的发生率。
JAMA Netw Open. 2022 Apr 1;5(4):e228879. doi: 10.1001/jamanetworkopen.2022.8879.
9
Myocarditis Cases After mRNA-Based COVID-19 Vaccination in the US-Reply.美国基于mRNA的COVID-19疫苗接种后的心肌炎病例——回复
JAMA. 2022 May 24;327(20):2020-2021. doi: 10.1001/jama.2022.5134.
10
Reactogenicity of Simultaneous COVID-19 mRNA Booster and Influenza Vaccination in the US.美国同时接种 COVID-19 mRNA 加强针和流感疫苗的反应原性。
JAMA Netw Open. 2022 Jul 1;5(7):e2222241. doi: 10.1001/jamanetworkopen.2022.22241.
引用本文的文献
1
EPIDEMIOLOGY OF FEBRILE SEIZURES DURING THE COVID-19 PANDEMIC: A CANADIAN IMMUNIZATION MONITORING PROGRAM-ACTIVE (IMPACT) STUDY.COVID-19大流行期间热性惊厥的流行病学：一项加拿大免疫监测项目-主动（IMPACT）研究。
Pediatr Infect Dis J. 2025 Feb 18;44(6):e230-3. doi: 10.1097/INF.0000000000004759.
2
mRNA Vaccines Against COVID-19 as Trailblazers for Other Human Infectious Diseases.针对新冠病毒的信使核糖核酸疫苗作为其他人类传染病的开拓者
Vaccines (Basel). 2024 Dec 16;12(12):1418. doi: 10.3390/vaccines12121418.
3
Parental experience with childhood COVID-19 vaccines and factors associated with parental hesitancy despite being vaccinated: findings of a cross-sectional analysis from Pakistan and implications for the future.父母对儿童新冠疫苗的体验以及尽管已接种疫苗但与父母犹豫态度相关的因素：来自巴基斯坦的横断面分析结果及对未来的启示
BMJ Open. 2024 Dec 10;14(12):e086877. doi: 10.1136/bmjopen-2024-086877.
4
COVID-19 Vaccine Reactogenicity Among Young Children.幼儿中的新冠病毒疫苗反应原性
JAMA Netw Open. 2024 Nov 4;7(11):e2447492. doi: 10.1001/jamanetworkopen.2024.47492.
5
Myocarditis associated with COVID-19 vaccination.与新冠病毒疫苗接种相关的心肌炎
NPJ Vaccines. 2024 Jun 28;9(1):122. doi: 10.1038/s41541-024-00893-1.
6
Factors Affecting Parental Intent to Vaccinate Against COVID-19 in the United States.影响美国父母接种新冠疫苗意愿的因素
Kans J Med. 2024 Jun 4;17(3):51-56. doi: 10.17161/kjm.vol17.21895. eCollection 2024.
7
Central nervous system manifestations following vaccination against COVID-19.接种新型冠状病毒疫苗后的中枢神经系统表现。
Brain Behav Immun Health. 2024 May 3;38:100788. doi: 10.1016/j.bbih.2024.100788. eCollection 2024 Jul.
8
Hesitation towards the COVID-19 vaccine in the United States: a digital ethnographic study.美国对 COVID-19 疫苗的犹豫：一项数字民族志研究。
Salud Colect. 2024 Mar 26;20:e4541. doi: 10.18294/sc.2024.4541.
9
Safety of Ancestral Monovalent BNT162b2, mRNA-1273, and NVX-CoV2373 COVID-19 Vaccines in US Children Aged 6 Months to 17 Years.原始单价BNT162b2、mRNA-1273和NVX-CoV2373新冠疫苗在美国6个月至17岁儿童中的安全性。
JAMA Netw Open. 2024 Apr 1;7(4):e248192. doi: 10.1001/jamanetworkopen.2024.8192.
10
COVID-19 Vaccine Safety Technical (VaST) Work Group: Enhancing vaccine safety monitoring during the pandemic.COVID-19 疫苗安全技术（VaST）工作组：在大流行期间加强疫苗安全监测。
Vaccine. 2024 Sep 17;42 Suppl 3(Suppl 3):125549. doi: 10.1016/j.vaccine.2023.12.059. Epub 2024 Feb 9.
本文引用的文献
1
Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months-5 Years - United States, June 2022.美国 2022 年 6 月关于在 6 个月至 5 岁儿童中使用 Moderna 和辉瑞-BioNTech COVID-19 疫苗的免疫实践咨询委员会临时建议。
MMWR Morb Mortal Wkly Rep. 2022 Jul 1;71(26):859-868. doi: 10.15585/mmwr.mm7126e2.
2
Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021.美国 2020 年 12 月至 2021 年 8 月报告的基于 mRNA 的 COVID-19 疫苗接种后心肌炎病例。
JAMA. 2022 Jan 25;327(4):331-340. doi: 10.1001/jama.2021.24110.
3
Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).疫苗不良事件报告系统（VAERS）中的安全性监测。
Vaccine. 2015 Aug 26;33(36):4398-405. doi: 10.1016/j.vaccine.2015.07.035. Epub 2015 Jul 22.
Zotero 插件